Note: Advance registration for Satellite Programs is not available to industry professionals. Industry professionals may register on-site for symposia on a first-come, first-served basis. Satellite programs offer sponsors the opportunity to provide professional attendees with comprehensive insights into important interventional topics and issues facing today's interventional specialists. The satellite programs schedule is comprised of Breakfast Meetings, Presentation Theater Programs (lunch sessions) and Evening Programs.
It should be noted that in theory if one was to consistently suppress your natural estrogen levels for a long period of time, this would negatively impact your health, including your cholesterol. Due to the ability of Letrozole- to inhibit estrogen so much, this should definitely be a concern to most users. However the research that has focused on the relationship between use of letrozole and cholesterol levels is rather inconsistent in it's findings. Many studies have concluded that the compound is detrimental to both a user's HDL and LDL cholesterol levels, while other research has found no link. Obviously individuals are best served to monitor their cholesterol while using any compound via blood tests however barring that, letrozole should simply not be run for extended periods of time if at all possible. Doing so could cause serious medical complications.
Along with the issues related to blood lipids is the fact that many users complain that their libido is dramatically reduced when using the compound. This is related to the fact that estrogen is partly responsible for the regulation of an individual's sex drive. Since Letrozole- is so potent it can often drive estrogen levels too low and this inhibits a user's libido. To avoid this users can lower dosages, but some anecdotally report that even extremely low doses of the drug can cause problems. If this is the case a less potent compound such as exemestane or anastrozole may be a more appropriate option.
John joins Amgen from Bristol-Myers Squibb (BMS), where he served as the global head of Clinical Development for marketed products as well as global clinical operations. Earlier roles at BMS included head of worldwide Medical and as a full development team lead in oncology. In these roles, John led a number of innovative changes to the company’s development and medical organizations and practices. He also served as chief medical officer, Europe, head of . Medical and vice president of Cardiovascular Medical. Prior to joining BMS, he was cardiovascular group leader at Pfizer, and was a member of the faculty staff at Kaiser Hospital in San Francisco.